BioCentury | Nov 3, 2020
Management Tracks

Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more

...will remain as an adviser. Kosaraju was president of medical device company Penumbra Inc. (NYSE:PEN).Ophthalmic company Oculis...
BioCentury | Feb 11, 2020
Product Development

Feb. 10 Product Development Quick Takes: Priority Review for Gilead CAR T cell therapy; plus Zai, Aquestive, Biohaven, Oculis, Blue Water, GlycoMimetics, Fluidi

...Alzheimer’s disease, obsessive-compulsive disorder and spinocerebellar ataxia. Phase II win for Oculis in macular edema Oculis...
BioCentury | Jan 5, 2018
Financial News

Oculis raises CHF20M series B

...participation by existing investors Brunnur Ventures and Silfurberg. Oculis also hired Riad Sherif as CEO. Oculis...
...Markabi, who was Alcon's SVP, CMO and head of R&D, will become Oculis' CSO, and Oculis...
...round led by Brunnur Ventures and Silfurberg. Oculis S.A., Lausanne, Switzerland Mary Romeo Actavis plc Alcon Inc. Allergan plc Novartis AG Oculis...
BioCentury | Jan 4, 2018
Financial News

Oculis raises CHF20M series B

...investors Brunnur Ventures and Silfurberg also participated. The round includes an initial CHF18 million tranche. Oculis...
...therapy is a topical dexamethasone formulation developed using the company's Solubilizing Nanoparticle (SNP) technology platform. Oculis...
...Markabi, who was Alcon's SVP, CMO and head of R&D, will become Oculis' CSO, and Oculis...
BioCentury | Aug 22, 2016
Financial News

Oculis completes venture financing

Oculis ehf , Reykjavik, Iceland Business: Drug delivery, Ophthalmic Date completed: 2016-08-16 Type: Venture financing Raised: Not disclosed Investors: Brunnur Ventures; Silfurberg Note: The amount raised is not disclosed. WIR Staff...
Items per page:
1 - 5 of 5
BioCentury | Nov 3, 2020
Management Tracks

Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more

...will remain as an adviser. Kosaraju was president of medical device company Penumbra Inc. (NYSE:PEN).Ophthalmic company Oculis...
BioCentury | Feb 11, 2020
Product Development

Feb. 10 Product Development Quick Takes: Priority Review for Gilead CAR T cell therapy; plus Zai, Aquestive, Biohaven, Oculis, Blue Water, GlycoMimetics, Fluidi

...Alzheimer’s disease, obsessive-compulsive disorder and spinocerebellar ataxia. Phase II win for Oculis in macular edema Oculis...
BioCentury | Jan 5, 2018
Financial News

Oculis raises CHF20M series B

...participation by existing investors Brunnur Ventures and Silfurberg. Oculis also hired Riad Sherif as CEO. Oculis...
...Markabi, who was Alcon's SVP, CMO and head of R&D, will become Oculis' CSO, and Oculis...
...round led by Brunnur Ventures and Silfurberg. Oculis S.A., Lausanne, Switzerland Mary Romeo Actavis plc Alcon Inc. Allergan plc Novartis AG Oculis...
BioCentury | Jan 4, 2018
Financial News

Oculis raises CHF20M series B

...investors Brunnur Ventures and Silfurberg also participated. The round includes an initial CHF18 million tranche. Oculis...
...therapy is a topical dexamethasone formulation developed using the company's Solubilizing Nanoparticle (SNP) technology platform. Oculis...
...Markabi, who was Alcon's SVP, CMO and head of R&D, will become Oculis' CSO, and Oculis...
BioCentury | Aug 22, 2016
Financial News

Oculis completes venture financing

Oculis ehf , Reykjavik, Iceland Business: Drug delivery, Ophthalmic Date completed: 2016-08-16 Type: Venture financing Raised: Not disclosed Investors: Brunnur Ventures; Silfurberg Note: The amount raised is not disclosed. WIR Staff...
Items per page:
1 - 5 of 5